Results 241 to 250 of about 8,138,914 (303)
Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells
Type I interferons differentially modulate autophagy and the response of pancreatic cancer cells to gemcitabine. IFNα2b stimulates autophagic flux and protects cells from gemcitabine‐induced cell death, contributing to chemoresistance. In contrast, IFNβ1a inhibits autophagosome formation and enhances gemcitabine‐induced cell death, resulting in ...
Lucy E. Bonilla +10 more
wiley +1 more source
Development and validity testing of a matrix to evaluate maturity of clinical pathways: a case study in Saskatchewan, Canada. [PDF]
Larson CL +5 more
europepmc +1 more source
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao +10 more
wiley +1 more source
Clinical pathways for Korean medicine: An implementation approach to impact on the clinical process and association with attitudes. [PDF]
Hyun E, Kim H, Kwak HY, Kim D.
europepmc +1 more source
Management of nonurgent common gastroenterology referrals using primary care clinical pathways: Clinical outcomes, health care use, and avoided costs. [PDF]
Novak K +9 more
europepmc +1 more source
Clinical pathways and operations management: it takes two to tango. [PDF]
Belien, Jeroen +3 more
core

